Multiple Myeloma
2055 clinical trials
118 cell line models
17 approved drugs
Multiple Myeloma
Molecular Synopsis
Drugs and clinical candidates

17 drugs have received FDA approval for Multiple Myeloma:

  • Bortezomib
  • Carfilzomib
  • Carmustine
  • Cyclophosphamide
  • Daratumumab

360 drugs have a clinical trial registered for Multiple Myeloma.

6635 compounds have been tested in Multiple Myeloma (4584 <= 500nM potency).

Sources:,, ChEMBL.

Clinical trials
There are 2055 clinical trials for Multiple Myeloma, 1544 of which have one or more drug interventions, 511 with no drug intervention.
Cell line models

There are 118 Cell Line Models for Multiple Myeloma.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from mesh condition terms to Multiple Myeloma:
  • Smoldering Multiple Myeloma
  • Multiple Myeloma
The following terms have been mapped from to Multiple Myeloma:
  • Multiple myeloma that has metastasized to bone
  • Multiple myeloma. It is used with bortezomib in patients who have already been treated with other chemotherapy
  • Broken bones and other bone problems caused by multiple myeloma or by solid tumors that have metastasized (spread) to bone. This use is approved for the Xgeva brand of denosumab
  • Multiple myeloma. It is given with dexamethasone. It is also used alone as maintenance therapy in patients who received an autologous stem cell transplant
  • Multiple myeloma in patients who have already received at least one other type of treatment